NCT07526311 Reducing Blood Loss During Myomectomy:Uterine Artery Ligation Vs Pericervical Tourniquet
| NCT ID | NCT07526311 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Myoma;Uterus |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-04-10 |
| Primary Completion | 2027-03-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-04-10 with a primary completion date of 2027-03-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare two surgical techniques for reducing blood loss during transabdominal myomectomy in women with symptomatic uterine fibroids. The main question it aims to answer is whether bilateral uterine artery ligation reduces intraoperative blood loss more effectively than pericervical mechanical tourniquet application, without increasing operative complications. Researchers will compare bilateral uterine artery ligation with pericervical mechanical tourniquet application during open myomectomy to evaluate blood loss and surgical safety. Participants will undergo elective transabdominal myomectomy and will be randomly assigned to one of the two vascular control techniques before myoma enucleation.
Eligibility Criteria
* Inclusion Criteria: * Female participants aged 25 to 48 years * Body mass index less than 35 kg/m² * Symptomatic uterine myomas requiring surgical treatment * Intramural myomas classified as FIGO types 3 to 6 * Diagnosis confirmed by transvaginal ultrasound and/or magnetic resonance imaging * Maximum diameter of the largest myoma 20 cm or less * Scheduled for elective transabdominal myomectomy * Able and willing to provide written informed consent * Exclusion Criteria: * Submucosal, intracavitary, pedunculated subserosal, cervical, or adnexal myomas * FIGO types 0, 1, 2, 7, or 8 myomas * History of pelvic inflammatory disease or peritonitis * Previous abdominal or pelvic surgery for non-obstetric causes * Previous uterine surgery * Use of hormonal therapy within the previous 3 months * Known bleeding disorder * Use of anticoagulant or antiplatelet therapy * Preoperative hemoglobin less than 10 g/dL * Body mass index 35 kg/m² or greater * Intraoperative conversion from myomectomy to hysterectomy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07526311 clinical trial?
This trial is open to female participants only, aged 25 Years or older, up to 48 Years, studying Myoma;Uterus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07526311 currently recruiting?
Yes, NCT07526311 is actively recruiting participants. Contact the research team at Magedalmohamady50@gmail.com for enrollment information.
Where is the NCT07526311 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07526311 clinical trial?
NCT07526311 is sponsored by Cairo University. The trial plans to enroll 40 participants.